Zvonko Milicevic

10PUBLICATIONS
26CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Behavioural epidemiologyFood properties (incl. characteristics and health benefits)PharmacogenomicsPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 29, 2025
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.

Yi Wen, Deven Lemen, Yanzhu Lin

|Jan 06, 2025
Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.

Kieren J Mather, Andrea Mari, Govinda Weerakkody

|Mar 01, 2023
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.

Tim Heise, J Hans DeVries, Shweta Urva

|Jan 05, 2021
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).

Juan P Frias, Enzo Bonora, Luis Nevarez Ruiz

|Jan 28, 2020
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.

Juan Pablo Frias, Michael A Nauck, Joanna Van

|Aug 01, 2019
Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.

Francesco Giorgino, Maria Yu, Axel Haupt

Pageof 2

Frequent Collaborators

5 joint publications

Axel Haupt

3 joint publications

Tamer Coskun

3 joint publications

Juan Pablo Frias

2 joint publications

Melissa K Thomas